Integra Thinks High Margin, Differentiated Portfolio Can Deliver A Transformative 2017

Integra LifeSciences surged to industry-leading 12% sales growth in 2016, and that's before it prepares to consolidate two of the biggest acquisitions in its history. What is the strategy behind the success of the specialty surgery, orthopedics and tissue tech company that is looking at another double-digit sales uplift in 2017?

Integra LifeSciences Holdings Corp.has been pleasing the market with its 2016 financial performance, 2017 M&A schedule and 2017–18 outlook. At some point, the group aims to reach aspirational targets of $2 billion in sales and 30% EBITDA margin as it establishes itself as a diversified medical technology group.

Its M&A has been making most of the headlines, but as Integra president and CEO Peter Arduini told investors on...

More from Growth

More from In Vivo